Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The Patient Access to Autoimmune Treatments (PAAT) Act would amend Medicare Part D rules to require prescription drug plan (PDP) sponsors to include, beginning in 2027, covered Part D drugs that are indicated and prescribed for autoimmune diseases, hemophilia, or Von Willebrand disease. The bill also prohibits PDP sponsors and Medicare Advantage prescription drug (MA–PD) plans from requiring prior authorization for such drugs more than once in any 12-month period, with exceptions for drugs normally used for 12 months or less, certain controlled substances (opioids, benzodiazepines, barbiturates, carisoprodol), and drugs subject to FDA Risk Evaluation and Mitigation Strategies (REMS).
Scope and mandate: liberals emphasize patient access gains; conservatives emphasize federal overreach into plan design.
Relative to its intended legislative type, this bill is a substantive policy change that is narrowly and directly drafted to amend Part D statutory requirements and to limit prior authorization frequency for specified categories of drugs.
The Patient Access to Autoimmune Treatments (PAAT) Act would amend Medicare Part D rules to require prescription drug plan (PDP) sponsors to include, beginning in 2027, covered Part D drugs that are indicated and prescribed for autoimmune diseases, hemophilia, or Von Willebrand disease.
The bill also prohibits PDP sponsors and Medicare Advantage prescription drug (MA–PD) plans from requiring prior authorization for such drugs more than once in any 12-month period, with exceptions for drugs normally used for 12 months or less, certain controlled substances (opioids, benzodiazepines, barbiturates, carisoprodol), and drugs subject to FDA Risk Evaluation and Mitigation Strategies (REMS).
The mandate is aimed at ensuring inclusion on formularies and limiting the frequency of reauthorization requirements for the specified categories of drugs.
On substance the bill is a targeted, administratively simple change that benefits patients with autoimmune and certain blood disorders and includes reasonable exceptions—features that improve its legislative prospects. However, it imposes new constraints on plan sponsors and likely increases costs to Part D plans/federal spending without explicit offsets, which raises opposition from industry and budget‑conscious lawmakers and makes enactment less certain. Passing the House is plausible; clearing the Senate and resolving any budgetary objections is the larger obstacle.
Relative to its intended legislative type, this bill is a substantive policy change that is narrowly and directly drafted to amend Part D statutory requirements and to limit prior authorization frequency for specified categories of drugs. It specifies the statutory text to be changed, names the affected entities, and provides effective dates, but it omits fiscal acknowledgment, detailed definitions, enforcement and reporting mechanisms, and several implementation details.
Scope and mandate: liberals emphasize patient access gains; conservatives emphasize federal overreach into plan design.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and mandate: liberals emphasize patient access gains; conservatives emphasize federal overreach into plan design.
A mainstream liberal would likely view the bill positively as a targeted patient-access measure that reduces administrative barriers for people with chronic autoimmune conditions and rare bleeding disorders.
They would see the prior-authorization limitation as a way to improve adherence and reduce interruptions in essential, often specialty, therapies.
They would also note that the bill does not change drug pricing directly and might push for stronger affordability measures alongside it.
A centrist/moderate would see the bill as a fairly narrow, pragmatic change aimed at improving continuity of care for specific patient groups, while also recognizing possible tradeoffs in cost and plan design.
They would appreciate the targeted nature (autoimmune and certain blood disorders) but want clearer fiscal analysis and guardrails to prevent unintended premium increases or reduced plan flexibility.
Overall, they would be cautiously supportive if accompanied by data collection, a budget estimate, and mechanisms to monitor downstream effects.
A mainstream conservative would be skeptical of the bill because it imposes a federal requirement on private Part D plan sponsors and MA–PD plans, limiting their formulary design and utilization-management tools.
While sympathetic to patients with chronic or rare conditions, they would prioritize plan flexibility, cost control, and concern about shifting costs to beneficiaries or taxpayers.
They would also worry about precedent: if Congress mandates inclusion and caps on prior authorization for one category, it may encourage similar mandates for other drug classes.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance the bill is a targeted, administratively simple change that benefits patients with autoimmune and certain blood disorders and includes reasonable exceptions—features that improve its legislative prospects. However, it imposes new constraints on plan sponsors and likely increases costs to Part D plans/federal spending without explicit offsets, which raises opposition from industry and budget‑conscious lawmakers and makes enactment less certain. Passing the House is plausible; clearing the Senate and resolving any budgetary objections is the larger obstacle.
The bill has not accumulated any surfaced votes yet.
Scope and mandate: liberals emphasize patient access gains; conservatives emphasize federal overreach into plan design.
On substance the bill is a targeted, administratively simple change that benefits patients with autoimmune and certain blood disorders and…
Relative to its intended legislative type, this bill is a substantive policy change that is narrowly and directly drafted to amend Part D statutory requirements and to limit prior authorization frequency for specified c…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.